Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance

  • Schuster H
  • Fagerberg B
  • Edwards S
 et al. 
  • 9

    Readers

    Mendeley users who have this article in their library.
  • 21

    Citations

    Citations of this article.

Abstract

Aim: To determine the effects of the peroxisome proliferator-activated receptor (PPAR) α/γ agonist tesaglitazar on serum levels of apolipoprotein (apo) A-I, apoB, and apoCIII in non-diabetic insulin-resistant subjects. Methods: This randomized, double-blind, multicentre, placebo-controlled trial examined the effect of tesaglitazar (0.1, 0.25, 0.5, and 1 mg) once daily for 12 weeks on apolipoprotein levels in 390 abdominally obese subjects with hypertriglyceridaemia. Results: Tesaglitazar dose-dependently increased serum concentrations of apoA-I (p < 0.009) and decreased concentrations of apoB (p < 0.0001), the apoB/apoA-I ratio (p < 0.0001), and apoCIII (p < 0.0001). Similar improvements were observed in all subgroups of subjects, where individuals were grouped according to age, gender, baseline body mass index, serum triglycerides and high-density lipoprotein cholesterol levels. Low-density lipoprotein particle concentrations were also dose-dependently reduced by tesaglitazar (p < 0.0001). Conclusion: Although tesaglitazar is no longer in clinical development, these data indicate that dual PPARα/γ agonism may be a useful pharmacological approach to improve the atherogenic dyslipidaemia associated with insulin resistance. © 2007 Elsevier Ireland Ltd. All rights reserved.

Author-supplied keywords

  • Apolipoprotein
  • Atherosclerosis
  • Dyslipidaemia
  • Hypertriglyceridaemia
  • Insulin resistance
  • Peroxisome proliferator-activated receptor

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free